risk of medullary thyroid cancer with glp 1 Ozempic and Wegovy increase cancer. “Use of GLP-1 RA for 1-3 years was associated increased risk of all thyroid (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) Glucagon-like peptide 1 receptor agonists
Pay in 4 interest-free payments of $5.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
![risk of medullary thyroid cancer with glp 1 Ozempic and Wegovy increase cancer. Use of GLP-1 RA for 1-3 years was associated increased risk of all thyroid (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) Glucagon-like peptide 1 receptor agonists](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40364-025-00765-3/MediaObjects/40364_2025_765_Fig1_HTML.png)
![risk of medullary thyroid cancer with glp 1 Ozempic and Wegovy increase cancer. Use of GLP-1 RA for 1-3 years was associated increased risk of all thyroid (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) Glucagon-like peptide 1 receptor agonists](https://cdn.prod.website-files.com/62aec59ac7c1e4f6f1719e4a/69130fb9ffc1b2514da57196_sZaQ-DpP9eOL5tchseCyX4AbJequVWVFMa5MNuraAS4.png)
![risk of medullary thyroid cancer with glp 1 Ozempic and Wegovy increase cancer. Use of GLP-1 RA for 1-3 years was associated increased risk of all thyroid (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) Glucagon-like peptide 1 receptor agonists](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-024-10192-9/MediaObjects/10555_2024_10192_Fig1_HTML.png)





















